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Purpose/Objective: Pulmonary emphysema (PE) is a non 
functional lung region due to destruction of the gas-
exchanging tissues. This information is never integrated into 
the radiotherapy (RT) plan for lung cancer (LC). With Myrian© 
software dedicated to radiology, an automatic delineation of 
PE can be processed and transferred to the treatment 
planning system (TPS). The main goal of this study was to 
evaluate the possibility to transfer and integrate the PE 
information into a radiotherapy plan, and calculate the 
volume of the healthy lung. 
Materials and Methods: We analyzed patients with LC and PE 
treated with RT excluding stereotactic treatments. All 
patients had a diagnostic CT before RT. The PE structure was 
delineated with Myrian© on the diagnostic CT and then 
transferred to the TPS. To permit a good correlation a 
deformable registration was performed between the 
diagnostic CT and the CT dedicated to RT with Velocity AI©. 
We created the healthy lung (HL) structure corresponding to 
the lung excluding the planning treatment volume (PTV) and 
the PE. We compared for each patient the lung-PTV volume 
to the HL volume.  
Results: Nine patients were included in our study, 2 women 
and 7 men. They all had intensity modulated RT. Mean total 
dose was 52.7 Gy (range, 36 – 66). The delay between the 
diagnostic and the planning CT varied between 3 to 111 days. 
The mean PE volume was 322 cm3 (range, 12 – 1394), and the 
mean variation between the lung-PTV volume and HL volume 
was 7.25% (range, 0.33% - 26.22%). Two patients had major 
volume variations respectively 14.8% and 26.22% 
corresponding to a PE volume of 668 and 1394 cm3. 
Conclusions: The transfer of the PE structure previously 
delineated with Myrian© to the TPS is readily feasible. 
Moreover, the difference between the HL and the lung-PTV 
structures can be considerable. It will be of interest to 
analyze the impact of integrating PE information to the 
radiotherapy plan to spare more HL for patients with PE.  
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Purpose/Objective: To evaluate our first cohort of non-small 
cell lung cancer (NSCLC) patients treated with definitive 
radiotherapy using volumetric modulated arc therapy (VMAT). 
Materials and Methods: We analysed 72 consecutive patients 
who received radical non-stereotactic radiotherapy with 
either VMAT (n=33) or 3D-CRT (n=39). Dosimetric comparison 
between the two groups was made. Radiation pneumonitis 
was graded according to the Common Terminology Criteria 
for Adverse Events (CTCAE) v. 4.0. The Chi-square test, 
Fishers exact test or Wilcoxon-Mann-Whitney test were used 
to compare the two groups. 
Results: A significantly higher proportion of VMAT treated 
patients had supraclavicular lymph node involvement (24% vs. 
3%, p=0.009). The risk of developing pneumonitis ≥ gr. 2 was 
12% in the VMAT group vs. 18% in the 3D-CRT group 
(p=0.497). The mean length of the PTV volume was 
significantly longer in the VMAT treated group (11.7 cm vs. 
10.0 cm, p=0.018), but there was no difference in V20Gy 
(24.0 vs. 23.2%, p=0.586), V5Gy (56.4 vs. 52.5%, p=0.228), 
V5Gy to contralateral lung (49.8 vs. 46.8%, p=0.417) or mean 
lung dose (13.7 vs. 14.0 Gy, p=0.782).  
Conclusions: VMAT treatment of NSCLC enabled the inclusion 
of patients with more advanced stages compared to 3D-CRT 
without any significant increase in lung dose.  
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Purpose/Objective: Stage IV NSCLC is characterized by a 
poor prognosis; nevertheless in patients with limited disease 
(1-5 metastases), called oligometastatic disease, has been 
observed a slightly better prognosis. The opportunity for local 
treatment in this stage of disease is not explored yet, but the 
management of oligometastatic disease is controversial. We 
evaluated the impact of a stereotactic body radiotherapy 
(SBRT) delivered in all active sites in the lung in patients with 
oligometastatic/oligorecurrent NSCLC. Response, survival, 
time to progression, sites of progression and toxicity were 
assessed. 
Materials and Methods: Twenty-nine lung metastases (within 
the lung parenchyma) in 22 patients affected by 
oligometastatic NSCLC were treated with SBRT to all active 
sites of disease. Inclusion criteria were controlled primary 
tumor with complete response or stable disease after 
surgery/radiotherapy/combined therapy,≤ 4 synchronous or 
metachronous lung metastases at the time of treatment,and 
no other active sites of distant metastasis. The prescribed 
dose was as follows: 23 Gy/single fraction for multiple 
lesions, 30Gy/single fraction for peripheral or small tumors (< 
30cc), and 45 Gy/3 fractions for centrally located or large 
tumors (≥ 30cc). 
Results: Response to treatment occurred as follow: complete 
response in 21% of lesions, partial response in 69% of 
metastases, stable disease in 10%. Ninety-one (91%) patients 
had complete metabolic response, 9% had a partial metabolic 
response. Median follow-up was 18 months. The 1-year and 2-
years OS was 86% and 49%, respectively. The 1-year and 2-
